Do atypical antipsychotic drugs enhance cognition in schizophrenia? -Preclinical and clinical evidence

DOI Web Site
  • Sumiyoshi Tomiki
    Department of Clinical Research Promotion, National Center of Neurology and Psychiatry

Bibliographic Information

Other Title
  • 非定型抗精神病薬は統合失調症の認知機能を改善するか？─前臨床および臨床研究のエビデンス─
  • 非定型抗精神病薬は統合失調症の認知機能を改善するか? : 前臨床および臨床研究のエビデンス
  • ヒテイケイ コウセイシンビョウヤク ワ トウゴウ シッチョウショウ ノ ニンチ キノウ オ カイゼン スル カ? : ゼン リンショウ オヨビ リンショウ ケンキュウ ノ エビデンス

Search this article

Description

In spite of controversy on the advantage of atypical antipsychotic drugs (AAPDs) to treat cognitive impairment in schizophrenia (CIS) , substantial subsets of patients benefit from these compounds. There is extensive evidence for the ability of AAPDs of various profiles, e.g. more potent affinity for serotonin (5-HT) receptor subtypes versus dopamine (DA)-D2 receptors and actions on multi-receptors, including mGluR2/3, to enhance cognition. Therefore, further investigations are needed into the heterogeneity in response to AAPDs within patients, specific cognitive domains relevant to outcome, and the neurobiological basis for the efficacy of AAPDs in model animals. The objective of this symposium involving presentations from Italy, USA, and Japan was to provide the evidence for the development of additional therapeutics for CIS.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top